Mavyret Approved as 8-Week Treatment for Hep C, Compensated Cirrhosis

MONDAY, Sept. 30, 2019 — Approval of Mavyret (glecaprevir and pibrentasvir) tablets has been expanded to eight-week treatment for treatment-naive patients aged 12 years and older with chronic hepatitis C virus (HCV) genotypes 1 through 6 and…
Source: Topamax